Posts tagged MD Anderson
Maxim ups Galena Biopharma price target to $4

Maxim Group raised its price target for Galena Biopharma (NASDAQ:GALE) to $4 from $1, saying the company has multiple programs moving forward, including NeuVax. The stock was quoted at $2.90 in afternoon trading on Dec. 2.

Read More
Roth adjusts DelMar Pharma price target to $12

Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday.

Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a senior exchange, either NASDAQ or NYSE-MKT, shortly.

Read More